Home › Catalysts
Quarter catalyst calendar
What lands in 3Q 2026, a look ahead to 4Q 2026, and the rest of the next twelve months below that. Dates are the company's own guidance as reported in our coverage — most are windows rather than fixed days, and each row says which it is. Click any catalyst to read the latest post on it.
Updated August 24, 2026 · 181 events
No catalysts match these filters.
This quarter · dated
20the company named a day or a month
- Aug 2026 EYPT Hold DURAVYU LUGANO topline thesis-defining
- Aug 2026 TENX Avoid TNX-103 topline thesis-defining
- Aug 2026 GPCR Buy aleniglipron Ph3 start notable
- Aug 2026 KYTX Buy Miv-cel Ph1 readout notable
- Aug 2026 TENX Avoid LEVEL Phase 3 levosimendan oral notable
- Aug 25, 2026 ZYME Spec buy Zanidatamab Ziihera PDUFA date thesis-defining
- Sep 2026 CNTB Spec buy Rademikibart Ph2 topline thesis-defining
- Sep 2026 DFTX Buy DT120 GAD Ph3 topline thesis-defining
- Sep 2026 IMMX Buy NXC-201 Ph2 topline thesis-defining
- Sep 2026 IRD Spec buy OPGx-BEST1 topline thesis-defining
- Sep 2026 KOD Hold Tarcocimab/KSI-501 Ph3 topline thesis-defining
- Sep–Oct 2026 RARE Buy GTX-102 Ph3 topline thesis-defining
- Sep 2026 EVMN Avoid EVO756 Ph2b topline major
- Sep 2026 SYRE Buy SPY072 SKYWAY Ph2 readout major
- Sep 2026 SYRE Buy SPY003 Ph1 interim notable
- Sep 2026 SYRE Buy SKYWAY RA sub-study filing notable
- Sep 2026 TYRA Watch SURF302 IR readout notable
- Sep 3, 2026 CLYM Buy CLYM116 Ph1 readout notable
- Sep 5–9, 2026 BEAM Watch BEAM-302 Ph1 readout material
- Sep 19, 2026 RARE Buy UX111 PDUFA date major
This quarter · guided to 3Q 2026
34
committed to the quarter, no finer date given
- 3Q 2026 DRTS Spec buy Alpha DaRT SCC pivotal topline thesis-defining
- 3Q 2026 KAPA Avoid ENV-105 prostate Ph2 topline thesis-defining
- 3Q 2026 ACET Watch Prula-cel Ph1 interim major
- 3Q 2026 GPCR Buy aleniglipron Ph2 topline major
- 3Q 2026 PHIO Avoid PH-762 filing major
- 3Q 2026 QURE Watch AMT-130 BLA filing major
- 3Q 2026 ACET Watch Prula-cel filing material
- 3Q 2026 BMEA Spec buy BMF-650 topline material
- 3Q 2026 CLRB Watch Iopofosine I 131 WM filing material
- 3Q 2026 CLRB Watch Iopofosine I 131 filing material
- 3Q 2026 DBVT Watch Viaskin Peanut 4-7 year-olds BLA material
- 3Q 2026 ELOX Watch Exaluren NMAS Ph2b start material
- 3Q 2026 GANX Buy GT-02287 Ph2 start material
- 3Q 2026 GPCR Buy ACCG-2671 Ph1 readout material
- 3Q 2026 OMER Buy YARTEMLEA narsoplimab EU decision material
- 3Q 2026 SCYX Watch SCY-770 Ph2 readout material
- 3Q 2026 VERA Buy Atacicept readout material
- 3Q 2026 ZYME Spec buy Zanidatamab HERIZON-GEA-01 interim material
- 3Q 2026 ACET Watch ADI-212 IND filing notable
- 3Q 2026 CLDX Buy CDX-622 Ph1 readout notable
- 3Q 2026 GLUE Buy MRT-2359 Ph2 start notable
- 3Q 2026 KAPA Avoid KROS-741 cMET inhibitor IND filing notable
- 3Q 2026 MDNAF Spec buy Bizaxofusp financing notable
- 3Q 2026 NGEN Spec buy NVG-291 filing notable
- 3Q 2026 OCGN Spec buy OCU410ST Ph2/3 interim notable
- 3Q 2026 PYPD Spec buy D-PLEX₁₀₀ MAA filing notable
- 3Q 2026 SCYX Watch SCY-247 Ph1 interim notable
- 3Q 2026 STRO Buy STRO-006 IND filing notable
- 3Q 2026 UNCY Avoid OLC commercial launch notable
- 3Q 2026 XENE Buy Azetukalner NDA filing notable
- late 3Q 2026 CUE Spec buy CUE-221 Ph2 topline thesis-defining
- late 3Q 2026 TECX Watch TX2100 topline major
- late 3Q 2026 CUE Spec buy CUE-221 IND filing material
- late 3Q 2026 OCGN Spec buy OCU410 Ph2 readout notable
Could land this quarter — no finer guidance
31
a six- to twelve-month window that overlaps this quarter by construction; shown in full on each company's page
- mid-2026 IMNM Watch IM-1340 IND filing notable
- 2H 2026 FBRX Exit FB102 Ph2 topline thesis-defining
- 2H 2026 INKT Watch agenT-797 topline thesis-defining
- 2H 2026 WVE Buy WVE-006 FDA approval thesis-defining
- 2H 2026 APGE Exit APG279 readout major
- 2H 2026 BBOT Watch BBO-8520 readout major
- 2H 2026 BBOT Watch BBO-10203 readout major
- 2H 2026 BBOT Watch BBO-11818 Ph1 interim material
- 2H 2026 DBVT Watch Viaskin Peanut Toddlers 1-3yo BLA material
- 2H 2026 ERAS Watch ERAS-4001 Ph1 interim material
- 2H 2026 FBRX Exit FB102 Ph1 topline material
- 2H 2026 JANX Buy JANX011 Ph1 interim material
- 2H 2026 TNGX Buy Vopimetostat monotherapy lung cancer Ph1 material
- 2H 2026 VRDN Buy VRDN-008 Ph1 readout material
- 2H 2026 ACET Watch in vivo CAR-T platform readout notable
- 2H 2026 ANNX Watch ANX1502 POC readout notable
- 2H 2026 APGE Exit Zumilokibart Ph3 start notable
- 2H 2026 ARVN Spec buy ARV-393 Ph1 interim notable
- 2H 2026 ENTA Spec buy EPS-3903 IND filing notable
- 2H 2026 INAB Watch INB-619 readout notable
- 2H 2026 INSM Watch ARIKAYCE Japan filing notable
- 2H 2026 RCKT Buy RP-A501 Danon disease Ph2 start notable
- 2H 2026 STRO Buy STRO-227 IND filing notable
- 2H 2026 VIR Buy VIR-5818 Ph1 readout notable
- 2H 2026 WVE Buy WVE-007 trial start notable
- 2H 2026 WVE Buy WVE-008 filing notable
- Late 2026 ABOS Spec buy Sabirnetug (ACU193) IV Ph2 topline thesis-defining
- Mid- and Late-2026 INAB Watch INB-200/INB-400 Ph2 interim major
- by the end of 2026 ARDX Avoid Tenapanor ACCEL enrollment done notable
- late 2026 IMNM Watch IM-1335 IND filing notable
- Late 2026 INAB Watch INB-100 enrollment done notable
Next quarter · 4Q 2026 preview
81
quarter-precision or finer
- 4Q 2026 ADCT Avoid ZYNLONTA + glofitamab topline thesis-defining
- 4Q 2026 AKBA Spec buy Vafseo VOCAL topline thesis-defining
- 4Q 2026 ANNX Watch Vonaprument Ph3 topline thesis-defining
- 4Q 2026 BMEA Spec buy Icovamenib topline thesis-defining
- 4Q 2026 BMEA Spec buy Icovamenib COVALENT-211 topline thesis-defining
- Oct 2026 CHRS Hold Casdozokitug Ph2 topline thesis-defining
- Oct 2026 CLDX Buy Barzolvolimab CSU Ph3 topline thesis-defining
- 4Q 2026 GUTS Spec buy Revita pivotal topline thesis-defining
- 4Q 2026 HELP Spec buy HLP003 Ph3 topline thesis-defining
- 4Q 2026 OCS Spec buy Licaminlimab pivotal topline thesis-defining
- 4Q 2026 PCVX Watch VAX-31 adult Ph3 topline thesis-defining
- 4Q 2026 PMVP Watch Rezatapopt topline thesis-defining
- 4Q 2026 VIR Buy ECLIPSE 1 Ph3 topline thesis-defining
- 4Q 2026 ZBIO Spec buy Obexelimab SLE Ph2 topline thesis-defining
- 4Q 2026 ZURA Watch Tibulizumab TibuSHIELD topline thesis-defining
- 4Q 2026 ABSI Buy ABS-201 PoC AGA interim major
- 4Q 2026 ACHV Watch Cytisinicline smoking cessation NDA filing major
- 4Q 2026 ACRS Buy ATI-052 Ph1 topline major
- 4Q 2026 ACRS Buy bosakitug topline major
- Oct 2026 CLDX Buy Barzolvolimab Atopic Dermatitis Ph2 topline major
- early 4Q 2026 CLNN Buy CNM-Au8 ALS NDA filing major
- 4Q 2026 INMB Watch CORDStrom/Ebstrocel MAA filing major
- 4Q 2026 KYTX Buy Miv-cel BLA filing major
- 4Q 2026 SPRB Spec buy TA-ERT tralesinidase alfa BLA filing major
- 4Q 2026 VYGR Watch VY7523 interim major
- 4Q 2026 ACHV Watch Cytisinicline smoking cessation corporate update material
- 4Q 2026 ALLO Spec buy ALLO-329 Ph1 interim material
- 4Q 2026 ANNX Watch Tanruprubart BLA filing material
- 4Q 2026 ATAI Exit VLS-01 topline material
- 4Q 2026 CGEM Buy CLN-978 readout material
- 4Q 2026 CLYM Buy Budoprutug SC formulation Ph1 readout material
- 4Q 2026 ENTA Spec buy EDP-978 Ph1 topline material
- 4Q 2026 IPSC Spec buy CNTY-813 IND filing material
- 4Q 2026 KYMR Buy KT-579 Ph1 readout material
- 4Q 2026 MLTX Watch Sonelokimab PsA topline material
- 4Q 2026 NAMS Watch PREVAIL obicetrapib interim material
- 4Q 2026 NKTR Watch Rezpegaldesleukin AA readout material
- 4Q 2026 ORKA Buy ORKA-001 readout material
- 4Q 2026 ABSI Buy ABS-201 Endometriosis Ph2 start notable
- 4Q 2026 ACRS Buy ATI-9494 IND filing notable
- 4Q 2026 CABA Buy SSc-ILD registrational study pivotal start notable
- 4Q 2026 CGEM Buy CLN-049 Ph2 readout notable
- 4Q 2026 CMPS Buy COMP360 TRD NDA filing notable
- 4Q 2026 CNTB Spec buy Rademikibart filing notable
- 4Q 2026 CUE Spec buy CUE-221 Ph2b start notable
- Oct 2026 EIKN Watch EIK1003 Ph1 readout notable
- 4Q 2026 ENTA Spec buy RESOLVE Ph2b start notable
- 4Q 2026 FDMT Watch 4D-710 AEROW Ph1 readout notable
- Oct 2026 GANX Buy GT-02287 Ph1 readout notable
- 4Q 2026 GLUE Buy MRT-8102 GFORCE-2 Ph2 start notable
- 4Q 2026 GLUE Buy MRT-8102 GFORCE-3 Ph2 start notable
- 4Q 2026 GPCR Buy ACCG-3535 / combination trial Ph1 notable
- 4Q 2026 KYTX Buy SPS BLA filing notable
- 4Q 2026 MDNAF Spec buy MDNA113 readout notable
- early 4Q 2026 NBP Spec buy Givastomig Ph3 start notable
- Oct 1, 2026 NKTR Watch REZOLVE-AD / REZOLVE-AA corporate update notable
- 4Q 2026 NVCT Spec buy NXP200 Ph1 readout notable
- 4Q 2026 RARE Buy UX701 Ph1 readout notable
- 4Q 2026 RCUS Spec buy ARC-20 cohorts cas+axitinib trial start notable
- 4Q 2026 REPL Buy RP2 readout notable
- 4Q 2026 RYTM Buy Setmelanotide HO commercial launch notable
- 4Q 2026 SABS Spec buy SAB-142 enrollment done notable
- 4Q 2026 SCYX Watch SCY-770 Ph2 start notable
- 4Q 2026 SLS Watch GPS Galinpepimut-S BLA filing notable
- 4Q 2026 VERA Buy Atacicept PIONEER Ph2 readout notable
- 4Q 2026 VYGR Watch VY1706 trial start notable
- Oct 23–27, 2026 TNGX Buy vopimetostat + RAS ON Ph1 major
- Oct 23, 2026 EIKN Watch EIK1005 Ph1 readout notable
- Oct 26, 2026 VNDA Avoid HETLIOZ® litigation ruling notable
- Nov 2026 PEPG Spec buy PGN-EDODM1 topline thesis-defining
- Nov 14, 2026 SMMT Buy ivonescimab NSCLC PDUFA date thesis-defining
- Nov 14, 2026 SMMT Buy ivonescimab NSCLC FDA decision thesis-defining
- Nov 28, 2026 PYPD Spec buy D-PLEX₁₀₀ PDUFA date thesis-defining
- Dec 2026 KOD Hold KSI-101 Ph3 topline thesis-defining
- late 4Q 2026 SLDB Spec buy SGT-003 FDA approval thesis-defining
- Dec 2026 ZNTL Spec buy Azenosertib China decision material
- Dec 2026 NRSN Avoid PrimeC Ph3 start notable
- Dec 3, 2026 EXEL Spec buy Zanzalintinib FDA approval material
- Dec 12, 2026 VNDA Avoid Imsidolimab FDA approval material
- Dec 23, 2026 LEGN Spec buy anito-cel Arcellx PDUFA date thesis-defining
- Dec 30, 2026 COGT Buy Bezuclastinib NonAdvSM PDUFA date thesis-defining
Further out · through 3Q 2027
46
the rest of the next twelve months, held to the same bar: quarter-precision or finer, or a wider window an outside source has confirmed
- 1Q 2027 CBIO Buy CR-001 Ph1 topline thesis-defining
- 1Q 2027 CRDL Spec buy CardiolRx MAVERIC topline thesis-defining
- 1Q 2027 OCGN Spec buy OCU400 Ph3 topline thesis-defining
- 1Q 2027 RNAC Buy Descartes-08 AURORA topline thesis-defining
- early 1Q 2027 TECX Watch TX45 topline thesis-defining
- 1Q 2027 TGTX Watch Subcutaneous ublituximab Ph3 topline thesis-defining
- 1H 2027 VOR Spec buy telitacicept Ph3 topline thesis-defining
- 1H 2027 XENE Buy Azetukalner MDD Ph3 topline thesis-defining
- 1Q 2027 APVO Avoid Mipletamig Ph2 readout major
- 1Q 2027 AUTL Spec buy BOBCAT MS Ph1 interim major
- 1Q 2027 CBIO Buy CR-001 topline major
- 1Q 2027 CGEN Watch COM701 interim major
- 1H 2027 IMTX Hold anzu-cel SUPRAME Ph3 interim major
- 1H 2027 MIST Buy CARDAMYST etripamil FDA approval major
- 1Q 2027 NAMS Watch PREVAIL obicetrapib readout major
- 1Q 2027 NKTR Watch Rezpegaldesleukin AD readout major
- 1Q 2027 SRPT Spec buy ELEVIDYS readout major
- 1Q 2027 TGTX Watch BRIUMVI (ublituximab) - ENHANCE Ph3 major
- 1Q 2027 AUTL Spec buy BOBCAT MS Ph2 readout material
- 1Q 2027 CBIO Buy CR-003 / SKB105 Ph1 readout material
- 1Q 2027 DYN Buy z-basivarsen pivotal topline material
- 1Q 2027 FDMT Watch Ixo-vec ARTEMIS Ph3 topline material
- 1Q 2027 LENZ Spec buy VIZZ China decision material
- 1H 2027 PCVX Watch VAX-31 infant Ph2 topline material
- 1Q 2027 PMVP Watch Rezatapopt NDA filing material
- 1Q 2027 TECX Watch TX45 readout material
- Jan 1, 2027 UNCY Avoid OLC FDA decision material
- 1H 2027 ENTX Watch EB612 IND filing notable
- Jan 2027 KAPA Avoid NCT05534646 readout notable
- 1Q 2027 OCGN Spec buy OCU400 BLA filing notable
- 1Q 2027 PMN Watch PMN310 filing notable
- 1Q 2027 SLDB Spec buy SGT-212 Ph1 readout notable
- Jan 21, 2027 DYN Buy z-rostudirsen FDA decision major
- Feb 2027 VRCA Watch Verrica financing notable
- 2Q 2027 FDMT Watch 4D-150 4FRONT-1 AMD Ph3 topline thesis-defining
- 2Q 2027 BMEA Spec buy Icovamenib COVALENT-212 topline major
- Apr 28, 2027 IMNM Watch Varegacestat FDA decision major
- by mid-2027 ELOX Watch Exaluren NMAS topline thesis-defining
- mid-2027 CBIO Buy CR-001 + Kelun-Biotech ADCs combination material
- as early as mid-2027 SANA Hold SG227 corporate update notable
- May 27, 2027 ZBIO Spec buy Obexelimab FDA approval material
- 2H 2027 ARDX Avoid Tenapanor ACCEL Ph3 topline thesis-defining
- 2H 2027 MPLT Spec buy ML-007C-MA VISTA Ph2 topline thesis-defining
- 2H 2027 NGNE Spec buy NGN-401 topline thesis-defining
- 2H 2027 FDMT Watch 4D-150 4FRONT-2 AMD Ph3 topline major
- 2H 2027 PCVX Watch VAX-A1 Ph1 topline material
How to read this
Deeper blue means more of the thesis turns on the event — not a view on the stock and not a prediction of the outcome. A thesis-defining readout and a routine trial start are both just events until they report.
Dates reflect company guidance as reported in Biotech Distilled coverage and are frequently windows rather than fixed dates. Not investment advice.